CPhi Japan to See Increased Participation of International Generic API Firms
CPhI日本博览会的2018年版将见证国际通用原料药公司和供应商的参与度增加,尽管市场被视为一种创新药物。这是因为,正如日本CPhI 2018年报告所显示的,经过多年的渐进式改革,日本的医药经济对仿制药和海外制造商变得非常欢迎,特别是那些能够将示范性监管记录与具有竞争力的定价相结合的制造商。通过2014年加入药物公约检查(PIC / S)计划,日本已向新进入者敞开大门。
药品展览将于2018年4月18日至20日在日本东京的Big Sight展览中心举行。CPhI日本展示的是跨越原料,合同服务,生物制药,机械,技术和包装的公司。该活动还将以2018年的成品剂型配方区(FDF)为基础,建立在API供应商基础日益多样化的基础上。
预计来自56个国家的超过21,000名参观者和来自30个国家的550名参展商将参加此次活动,突显该国不断发展的国际化。
CPhI日本会议将展示来自厚生劳动省(MHLW),医药和医疗器械代理机构,日本通用和生物仿制药协会以及日本制药商协会的见解。日本的另一项重大发展,特别是对新进入市场的企业而言,是2018年“定价体系改革和引入成本效益评估”所带来的影响,会议将在会上发表主题演讲。相反,对于该地区的买家而言,获得国际合作伙伴的信息和渠道对于建立强大的供应链是不可或缺的,该活动还将举办一个“国际原料药采购论坛” - 专门为赋予政府对80%仿制药市场的要求到2020年渗透。
“CPhI日本是该国更广泛的市场趋势的准确先驱,今年我们看到对仿制药和生物制品,尤其是生物仿制药的兴趣正在加速上升 - 市场以前已经适应这种趋势。但由于放松管制和简化新药审批流程,所有产品类别(包括创新药物)的国际利益和投资也普遍增加,“UBM日本CPhI品牌经理Laura Murina女士评论道。
2026-10-08
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
GLP-1 API Route to U.S. Abruptly Narrows: FDA Heavily Penalizes U.S. Compounding Pharmacy and Bypasses Warning Letter to Ban Chinese Factory
-
India Proposes New GMP Rules for Clinical Trial and API Manufacturing
-
CPHI & PMEC India 2026
-
CPHI & PMEC India 2026
-
CPHI & PMEC China 2023: A Global Pharmaceutical Industry Exchange and Cooperation Platform
-
【CPHI China 2023】Day 3 -- The CPHI China exhibition has come to a successful end, and Echemi has received high praise and recognition.
-
【CPHI China 2023】Day 2 -- Echemi teams up with CPHI China to hold overseas buyer matching event, helping pharmaceutical companies expand into international markets.
-
【CPHI China 2023】Day 1 -- ECHEMI.com helps transform and upgrade the pharmaceutical industry
-
Overview of China's API industry in 2023
-
Global Analysis of Active Pharmaceutical Ingredient (API)
Recommend Reading
-
U.S. Strikes Three Iranian Tankers as “Tanker-for-Tanker” Escalation Raises Chemical Shipping Risk
-
Do You Know the Food Zero Additives?
-
China’s Titanium Dioxide Giant Makes a Move: LB Group Acquires UK Venator Assets
-
EFSA Unable to Confirm Safety of Fusarium flavolapis Fungal Protein as a Novel Food
-
Trump Tariff "Boomerang": $2.5 Billion Polysilicon Factory Faces Shutdown Crisis
-
Business Society’s September 7, 2026 Melamine Market Outlook: Fluctuating Trend
-
Carbon Tetrachloride: Uses, Hazards, and Industrial Applications
-
Essential Demand Drives Acrylic Market to Trade Sideways
-
Acetophenone: Properties, Uses, and Applications
-
Business Society’s September 7, 2026 Methanol Market Outlook: Deep Correction